Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 6/20 | 0.80 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.80 |
| ▸ | ATP4A | P20648 | 5/20 | 0.33 |
| ▸ | ATP4B | P51164 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668068 | 1.00 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BNPC1 | |
| SCHEMBL26316661 | 0.97 | ERBB2 (0.76) | ERBB2MINK1ATP4AATP4BNPC1 | |
| SCHEMBL5532797 | 0.93 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BRAB9A | |
| SCHEMBL5532795 | 0.93 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BRAB9A | |
| SCHEMBL22397926 | 0.92 | ERBB2 (0.81) | ERBB2MINK1ATP4AATP4BFFAR1 | |
| SCHEMBL28480663 | 0.92 | ERBB2 (0.81) | ERBB2MINK1ATP4AATP4BFFAR1 | |
| SCHEMBL22398091 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BFFAR1 | |
| SCHEMBL22398052 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BCYP19A1 | |
| SCHEMBL22397904 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BNPC1 | |
| SCHEMBL22398093 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024200612-A1 | INHIBITORS OF URIDINE CATABOLISM AND/OR TRANSPORT FOR THERAPY | Université de Lausanne (CH) | 2024-10-03 | — | — | WO | claimed |
| WO-2024200612-A1 | INHIBITORS OF URIDINE CATABOLISM AND/OR TRANSPORT FOR THERAPY | Université de Lausanne (CH) | 2024-10-03 | — | — | WO | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-8017735-B2 | Comprising one or more binding compositions comprising a member selected from a light chain amino acid sequence which comprises CDR-L1 and a heavy chain amino acid sequence which comprises CDR-H1 in association with one or more chemotherapeutic agents; cancer therapy | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20100286063-A1 | GNRH agonist combination drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040116330-A1 | Diagnosing or specifying a growth factor receptor expressed in cancer cells, and selectively inhibiting all or a part of the growth factor receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1424080-A1 | GNRH AGONIST COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6716863-B2 | TYROSINE KINASE INHIBITORS; ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | TASAKA AKIHIRO (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1350792-A1 | MEDICINAL COMPOSITIONS IMPROVED IN SOLUBLITY IN WATER | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| EP-1350793-A1 | MEDICINAL COMPOSITIONS HAVING IMPROVED ABSORBABILITY | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20020173526-A1 | Heterocyclic compounds their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | ERBB2 173/4885MINK1 3941/4885ATP4A 3496/4885 |
| US-20100286063-A1 | GNRH agonist combination drugs | GNRHR, FSHR, EDNRA | ERBB2 1062/4885MINK1 1352/4885ATP4A 4481/4885 |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | ABL1, ROS1, MAPK1 | ERBB2 6/4885MINK1 340/4885ATP4A 3622/4885 |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | ERBB2 2558/4885MINK1 1781/4885ATP4A 1129/4885 |
| US-20020173526-A1 | Heterocyclic compounds their production and use | ABL1, ROS1, MAPK1 | ERBB2 8/4885MINK1 258/4885ATP4A 3772/4885 |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | ERBB2, EGFR, ABCG2 | ERBB2 1/4885MINK1 3888/4885ATP4A 2449/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | ERBB2 3959/4885MINK1 311/4885ATP4A 3671/4885 |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | EGFR, ERBB2, ERBB3 | ERBB2 2/4885MINK1 2919/4885ATP4A 3409/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | ERBB2 734/4885MINK1 3935/4885ATP4A 3398/4885 |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | EGFR, ERBB2, ERBB3 | ERBB2 2/4885MINK1 3017/4885ATP4A 2085/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | ERBB2 2443/4885MINK1 1986/4885ATP4A 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.